Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lymphocyte‐activation gene‐3, an important immune checkpoint in cancer

14 Jun 2016

Abstract excerpt

Immunotherapy has recently become widely used in lung cancer. Many oncologists are focused on cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed cell death ligand-1 (PD-L1) and programmed cell death-1 (PD-1). Immunotherapy targeting the PD-1/PD-L1 checkpoints has shown promising efficacy in non-small cell lung cancer (NSCLC), but questions remain to be answered. Among them is whether the simultaneous...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Lung Cancer Research Studies
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27297395
DOI: 10.1111/cas.12986

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lymphocyte‐activation gene‐3, an important immune checkpoint in cancerPMID 27297395Read ↗

LAG-3 and PD-1/PD-L1 inhibitors might become a promising treatment for small cell lung cancerSemantic proximity Read ↗

LAG-3 and PD-1/PD-L1 Inhibitors Might Become a Promising Treatment for Small Cell Lung CancerSemantic proximity Read ↗

LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.Semantic proximity Read ↗

Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentialsSemantic proximity Read ↗

Gene of the month: lymphocyte-activation gene 3 (LAG-3)Semantic proximity Read ↗

Understanding LAG-3 SignalingSemantic proximity Read ↗

Lymphocyte activating gene 3 protein expression in nasopharyngeal carcinoma is correlated with programmed cell death-1 and programmed cell death ligand-1, tumor-infiltrating lymphocytesSemantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitor remodels tumor microenvironment by upregulating LAG-3 in advanced non-small-cell lung cancer.Semantic proximity Read ↗

LAG-3: from molecular functions to clinical applicationsSemantic proximity Read ↗

Pan-cancer and single-cell analysis reveal dual roles of lymphocyte activation gene-3 (LAG3) in cancer immunity and prognosis.Semantic proximity Read ↗

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4Semantic proximity Read ↗

Coexpression of LAG-3 and PD-L1 in tumor infiltrating immune cells predicts worse outcome in clear cell renal cell carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.